Revolution Medicines publishes corporate deck outlining RAS(ON) inhibitor pipeline targeting RAS-driven cancers
RVMD•Daraxonrasib clinical and regulatory updates
- Revolution Medicines highlighted Phase 3 RASolute 302 data in previously treated metastatic pancreatic cancer for daraxonrasib versus IV chemotherapy.
- Overall survival hazard ratio 0.40, a 60% reduction in risk of death; median OS 13.2 months versus 6.7 months.
- U.S. FDA accepted the daraxonrasib NDA for review; EMA began a phased review of the marketing authorization application.
- Expanded access program supplied daraxonrasib for physicians on behalf of more than 2,000 patients across almost all 50 states.
Corporate deck highlights RAS(ON) inhibitor pipeline
Revolution Medicines highlighted its RAS(ON) inhibitor pipeline targeting RAS-driven cancers, with a pipeline update centered on oral RAS(ON) inhibitors, including zoldonrasib in combination regimens for KRAS G12D pancreatic cancer.
